Hewlett Packard Enterprise Co vs Zimmer Biomet Holdings Inc — how do they compare? Hewlett Packard Enterprise Co trades at $73.68 (market cap $94.25B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Hewlett Packard Enterprise Co is far larger — about 5.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HPE | ZBH | |
|---|---|---|
Market Cap | $94.25B | $16.95B |
Volume | 16,060,854 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $72.12 | $103.98 |
52-Week Low | $20.01 | $79.58 |
Typical Hold Time | 33 Days | 89 Days |
Enterprise Value | $108.28B | $24.02B |
Dividend Yield | 0.8% | 1.08% |
Signals from Pluang's Aura AI — not financial advice
HPE trades at $73.46, up 1.87% today and near its 52-week high, driven by strong AI infrastructure demand. The stock has a bullish technical signal with moving averages supporting the uptrend. Recent earnings beats, including Q2 2026 EPS of $1.11 versus $0.932 expected, highlight operational strength. A $1.2 billion AI server order from Vultr and raised revenue guidance fuel optimism, though valuation ratios like a P/E of 36.6 suggest premium pricing.
Outlook remains positive with AI-driven growth catalysts, but risks include high valuation and competitive pressures. Analyst consensus is mixed with a $70.35 price target, slightly below current levels. Net income margin compression in 2025 to 0.16% warrants monitoring, though 2026 projections show recovery. The stock's momentum hinges on execution of AI orders and margin expansion.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →